



ABIVAX Provides Corporate Update and Reports 2016 Half Year Financial Results

September 20, 2016

ABIVAX Provides Corporate Update and Reports 2016 Half Year Financial Results

- **ABX464 second Phase IIa (HIV/AIDS) on track, top line data expected before year end 2016**
- **Lead compound against Chikungunya identified using ABIVAX' proprietary anti-viral platform**
- **Lead compound against Ebola identified using ABIVAX' polyclonal antibody technology platforms**
- **Robust cash position (28,1 M€) expected to cover ABIVAX financial needs at least until the end of 2017**

Paris, September 20th 2016 - ABIVAX (Euronext Paris : FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today provides a corporate update and reports its half-year financial results as of June 30 2016. The half-year financial report is available on the company's website (Investors – Financial Reports). In compliance with regulations, the half-year financial results were reviewed, on a limited basis, by the company's statutory auditors and were approved by ABIVAX's Board of Directors on September 19th.